• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcturus Therapeutics Holdings Inc (NQ:ARCT)

    8.185 -0.115 (-1.39%)
    Streaming Delayed Price Updated: 12:56 PM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Arcturus Therapeutics Holdings Inc

    < Previous 1 2 3 4 5 Next >
    News headline image
    Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Attend Upcoming Investor Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Attend Upcoming Investor Conferences
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
    Via Investor Brand Network
    Topics Artificial Intelligence
    Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Arcturus Therapeutics to Attend Upcoming Investor Conferences
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Attend Upcoming Investor Conferences
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
    From Arcturus Therapeutics
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Attend Upcoming Investor Conferences
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    News headline image
    Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
    From Arcturus Therapeutics Holdings Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.